ARROWHEAD PHARMACEUTICALS, INC. Impairment of Intangible Assets, Finite-lived
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Impairment of Intangible Assets, Finite-lived of $0 for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2025-11-25
- ARROWHEAD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2022-09-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2013-09-30 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2013-06-30 was $1.31M.
- ARROWHEAD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2025 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2024 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00.
- ARROWHEAD PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month | Impairment of Intangible Assets, Finite-lived 122 month |
|---|---|---|---|---|---|
| 2025-09-30 | $0.00 10-K · filed 2025-11-25 | ||||
| 2024-09-30 | $0.00 10-K · filed 2025-11-25 | ||||
| 2023-09-30 | $0.00 10-K · filed 2025-11-25 | ||||
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | $0.00 10-K · filed 2024-11-26 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | ||||
| 2021-09-30 | $0.00 10-K · filed 2022-11-28 | ||||
| 2013-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-25 | $1.31M derived: sum of 2 quarters · filed 2014-11-25 | $1.31M 10-K · filed 2014-11-25 | ||
| 2013-06-30 | $1.31M 10-Q · filed 2013-08-07 | $1.31M 10-Q · filed 2013-08-07 | $1.31M 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |